LDLR and atherosclerosis: Beyond its role in cholesterol metabolism, PCSK9 has been implicated in various pathological processes, including atherosclerosis, inflammation, and even cancer, as it influences the degradation of several receptors beyond LDLR, such as CD36 and MHC-I, which are involved in fatty acid uptake and immune responses, respectively [5, 6].